|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
NEIMETH INTERNATIONAL PHARMACEUTICALS PLC
Main Activities: Chemical Manufacturing - Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name NEIMETH INTERNATIONAL PHARMACEUTICALS PLC Headquarters 1, Henry Carr Street,Ikeja Industrial Estate,Ikeja, Lagos ; Lagos; Lagos; P.M.B. 21111 |
Status: Listed Legal Form: Other non-liability limited Operational Status: Operational ISIN CODE : NGNMTHINDLN2 Financial Auditors: Akintola Williams Deloitte (2010) Incorporation Date: August 15, 1957 Tel: +(234 1) 497 3730-4 |
|
Company Description |
| Neimeth International Pharmaceuticals plc is involved in the manufacturing and sales of pharmaceuticals, chemicals and animal health products .The Company had operated in Nigeria for 40 years, producing, marketing, and distributing Pfizer brands of pharmaceutical and veterinary products in tablets, capsules, ointment/cream, powder, injectables, and oral liquid forms. During the 40 year period (1957-1997), the company established the first pharmaceutical manufacturing plant in Nigeria at Aba, which | ||
|
||
Company Analysis |
| According to the Consolidated - Audited financial statement for the Year of 2009, total net operating revenues decreased with -5.23%, from NGN 1,973,296 thousands to NGN 1,870,120 thousands. Operating Results decreased from NGN 284,321 thousands to NGN -282,113 thousands. The results of the period reached NGN -455,208 thousands at the end of the period against NGN 98,267 thousands last year. Return on equity (Net income/Total equity) went from 6.01% to -42.43%, the Return On Asset (Net income / Total Asset) went from 3.00% to -15.76% and the Net Profit Margin (Net Income/Net Sales) went from 4.98% to -24.34% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 169.27% compared to 100.14% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 3.17 to 1.97 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2010 Y (cons) |
2009 Y (cons) |
|
 | ||
| Non-Audited | Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
2,786,056 |
2,888,729 |
| ||
Current Assets |
2,318,796 |
2,486,717 |
| ||
Total Liabilities |
1,835,316 |
1,815,942 |
| ||
Shareholders Equity |
950,740 |
1,072,787 |
| ||
Current Liabilities |
1,282,481 |
1,259,800 |
| ||
| * All the accounts are in NGN. | ||
Income Statement
| ||
Total Operating Revenue |
1,933,733 |
1,870,120 |
| ||
Operational Profit (Loss) |
11,334 |
-282,113 |
| ||
Net Profit (Loss) |
-126,133 |
-455,208 |
| ||
| * All the accounts are in NGN. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
-4.53% |
-15.76% |
| ||
Annualised Return on Assets (ROA) |
-4.53% |
-15.76% |
| ||
Return on Equity (ROE) |
-13.27% |
-42.43% |
| ||
Annualised Return on Equity (ROE) |
-13.27% |
-42.43% |
| ||
Return on Sales (ROS) |
-6.67% |
-24.38% |
| ||
Return on Capital |
-11.08% |
-36.33% |
| ||
Gross Profit Margin |
49.61% |
59.22% |
| ||
Operating Profit Margin |
1.09% |
-6.25% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
1.87x |
2.15x |
| ||
Inventory Turnover |
0.90x |
0.64x |
| ||
Current asset turnover |
0.82x |
0.75x |
| ||
Fixed-asset turnover |
4.05x |
4.64x |
| ||
Asset Turnover |
0.68x |
0.65x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
-6,596 |
-178,078 |
| ||
EBITDA |
63,701 |
-113,995 |
| ||
Enterprise value |
1,940,660 |
4,045,358 |
| ||
Enterprise Value / EBITDA |
30.47 |
-35.49 |
| ||
Bookvalue (BV) |
2,294,963 |
2,172,074 |
| ||
Net Cash |
-1,212,133 |
-1,245,458 |
| Liquidity Ratios | ||
| ||
Current Ratio |
180.81% |
197.39% |
| ||
Quick ratio |
98.56% |
103.56% |
| ||
Doom's day ratio |
5.49% |
1.14% |
| Leverage Ratios | ||
| ||
Leverage ratio |
293.04% |
269.27% |
| ||
Interest Coverage Ratio |
-5.09% |
-135.05% |
| ||
Debt to equity |
193.04% |
169.27% |
| ||
Debt to total assets |
65.88% |
62.86% |
| ||
Long Term Debt to Capital |
57.37% |
57.52% |
| ||
Debt / Enterprise Value |
25.31% |
17.72% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
23.86 |
-29.33 |
| ||
Price/Book Ratio |
0.68 |
1.56 |
| ||
Market Cap / Net cash |
-1.25 |
-2.68 |
| Trend Ratios | ||
| ||
Revenue Trend |
101.25% |
95.93% |
| ||
Net Income Trend |
27.71% |
-463.24% |
| ||
Operating Income Trend |
3.7% |
-62.76% |
| ||
 |